BioBiz Buzz

The radioligand therapy market will be worth $42 billion by 2032. However, beneath the headline-grabbing acquisitions lies a complex web of technical and commercial challenges that threaten to limit patient access to these revolutionary cancer treatments. The path to successful radioligand development is fraught with obstacles, from the "melting ice cube" logistics of short-lived radioisotopes to the renal toxicity pitfalls that plague small-molecule approaches.

In this episode of BioBiz Buzz, your host Mike Ward sits down with David Bejker, CEO of Swedish biotech Affibody, to explore how engineered protein platforms are systematically addressing the industry's most pressing challenges. With over 20 years of radioligand development experience and more than 200 patients dosed, Affibody has developed a unique solution: engineered proteins 25 times smaller than traditional antibodies that deliver targeted radiation with unprecedented precision while avoiding the toxicity issues that have historically limited therapeutic efficacy.

Bejker reveals how Affibody's platform overcomes critical industry bottlenecks — from manufacturing stability at extreme temperatures to rapid tissue penetration and optimized pharmacokinetics. The conversation delves into the company's HER2-targeting program, which addresses a huge market opportunity. It explores how their technology differentiates from the peptide and antibody approaches dominating current billion-dollar acquisitions by Bristol Myers Squibb, Eli Lilly, and AstraZeneca.

Beyond the technical innovations, this episode examines Affibody's strategic partnerships with industry giants, demonstrating how specialized biotechs can leverage established infrastructure to accelerate patient access while maintaining focus on core innovation. From bacterial production systems that slash manufacturing costs to companion diagnostics that enable personalized treatment selection, Bejker illustrates how thoughtful platform design can transform radioligand therapy from a niche treatment to a scalable healthcare solution.

Essential listening for biotech executives, investors, and industry professionals seeking to understand how the next generation of radioligand companies is solving the challenges that will determine which treatments reach patients—and which billion-dollar bets pay off.

● Feedback

● Subscribe (Get notified when new episodes are available. NO marketing!)

● Disclaimer  

● LinkedIn

By 2040, the World Health Organization predicts that one in two people will be diagnosed with cancer in their lifetime. Yet the traditional pharmaceutical industry remains trapped in a devastating cycle: developing next-generation cancer drugs typically takes years, costs up to $2.5 billion, and often fails to deliver effective treatments to desperate patients. But what if there was a revolutionary way to shatter these constraints?

In this episode of BioBiz Buzz, your host Mike Ward sits down with Dr. Matthias Wiedenfels, CEO of BioCopy, the Swiss-German biotech company that's completely rewriting the playbook for cancer drug development. Under Wiedenfels' visionary leadership, recognized by WirtschaftsWoche magazine as one of Germany's biotech pioneers of the coming decade, BioCopy has created an unprecedented AI-powered platform that's achieving what seemed impossible.

The numbers are staggering: BioCopy is slashing drug development timelines from three years to just 12 months and testing 25,000 drug candidates in parallel instead of the traditional 10-100. Its proprietary ValidaTe technology performs large-scale precision screening of cancer targets, while its end-to-end automated laboratory mimics industrial production processes from day one.

But BioCopy's true innovation lies deeper. While conventional approaches focus on surface cancer markers, BioCopy homes in on hidden internal targets that make up 75% of all potential targets, a virtually untapped treasure trove that promises unprecedented specificity and safety. Its AI-driven platform generates massive datasets of unmatched quality, enabling it to develop highly complex multi-specific biotherapeutics that directly connect immune cells to cancer cells with minimal risk to healthy tissue.

This episode exposes the brutal realities of traditional drug development and unveils how artificial intelligence, automation, and visionary leadership are converging to potentially save millions of lives. As cancer rates soar globally, discover how one company's radical approach could transform the fight against humanity's most persistent enemy.

Don't miss this essential conversation about the future of precision medicine, the power of AI in biotechnology, and why the next decade could mark a turning point in our battle against cancer.

● Feedback

● Subscribe (Get notified when new episodes are available. NO marketing!)

● Disclaimer  

● LinkedIn

ReproNovo demonstrated continued investor interest in the area of reproductive medicine by closing a $65 million Series A round earlier this year. In this episode, ReproNovo’s CEO and co-founder Jean Duvall joins your host, Cormac Sheridan, to discuss the company’s development strategy and how it put together the financing deal.

ReproNovo is not a typical Series A company. It has secured rights to two clinical-stage assets that originated in large pharma companies. Novartis originally developed leflutrozole (RPN-001) before licensing the molecule to Mereo Biopharma. Merck originated nolasiban (RPN-002), which ObsEva took into phase 3 development. As well as having well-understood mechanisms of action and supportive clinical data, the two molecules address clear unmet medical needs and have significant commercial prospects. 

Although neither program went the full distance under their original developers, ReproNovo is now subtly repositioning them to optimise their potential. Leflutrozole, an aromatase inhibitor, is currently undergoing a phase 2 trial in the U.S. for the future indication of infertility in men with low serum testosterone. Nolasiban, an oxytocin receptor antagonist, is in preparation for two phase 2 studies next year. The company will evaluate its potential to improve the success rates of in vitro fertilisation procedures and to ameliorate adenomyosis, an under-recognised condition caused by tissue from the lining of the uterus growing into the muscular area of the uterus.

● Feedback

● Subscribe (Get notified when new episodes are available. NO marketing!)

● Disclaimer  

● LinkedIn

In this episode of BioBiz Buzz, your host Shani Alexander is joined by Werner Lanthaler, founder and CEO of WLan Holding, to chart the seismic transformation underway in medical technology. Discover how the convergence of multi-omic diagnostics, AI-driven sensors, and smart implants is creating unprecedented value, from AI-enhanced stethoscopes that detect early heart murmurs to wearable devices that predict disease trajectories. 

Werner explains why platform-based approaches, combining mass-spec diagnostics across multiple diseases, are capturing investors’ interest and how family offices are redefining “unicorn” potential through scalable, multi-use technologies. 

Learn why healthy, productive aging has become the mission-critical market, how Big Tech and global competitors are reshaping healthcare, and what emerging MedTech startups must do to secure funding in this high-stakes arena. 

Tune in now to unlock the roadmap for tomorrow’s intelligent devices. 

● Feedback

● Subscribe (Get notified when new episodes are available. NO marketing!)

● Disclaimer  

● LinkedIn

As the opioid crisis continues to devastate communities worldwide, millions suffering from chronic and neuropathic pain face a critical dilemma: enduring debilitating pain or risking addiction with traditional opioid medications. In this episode of BioBiz Buzz, host Mike Ward explores one of modern medicine's most pressing challenges with Per von Mentzer, CEO of PharmNovo, a pioneering Swedish biotech company developing revolutionary non-addictive pain treatments. 

The conversation delves deep into PharmNovo's groundbreaking approach through their lead candidate PN6047, a selective delta-opioid receptor agonist that promises to deliver powerful pain relief without the addiction risks or sedation effects associated with conventional mu-opioid receptor targeting drugs. Von Mentzer explains how this innovative mechanism specifically addresses neuropathic pain - a particularly challenging condition caused by nerve damage that affects millions of patients with diabetes, chemotherapy side effects, and various injuries.

This episode offers hope for the future of pain management, suggesting that the next five to ten years will witness a fundamental shift toward safer, non-addictive treatments becoming the standard of care. The interview provides both scientific insight into delta-opioid receptor targeting and a realistic perspective on the challenges and opportunities in developing safer pain medications for millions of patients worldwide who desperately need effective alternatives to traditional opioids.

● Feedback

● Subscribe (Get notified when new episodes are available. NO marketing!)

● Disclaimer  

● LinkedIn

In 2024, despite a challenging global financial climate, Switzerland’s biotech sector showed remarkable resilience, maintaining steady revenues of CHF 7.2 billion while achieving a 22% increase in capital investment.

In this episode of BioBiz Buzz, host Mike Ward interviews Michael Altorfer, CEO of the Swiss Biotech Association, to discuss the findings and implications of the Swiss Biotech Report 2025. The conversation focuses on the report’s central theme, "The Power of International Alliances", and examines how cross-border collaborations have become a key factor in the success of the Swiss biotech industry, with 80% of patents originating from international partnerships.   

Listeners will hear a comprehensive discussion about the increasing divide between well-funded serial entrepreneurs and emerging innovators. It will explore the evolving strategies that Swiss companies are using to access capital and how the sector is responding to the stagnation in public markets. Additionally, the episode will address important questions regarding talent retention, the sustainability of employment growth in manufacturing, and the risks posed by rising global protectionism and regulatory challenges.

Altorfer shares insights on how Switzerland’s collaborative culture, regulatory harmonization efforts, and academic excellence have enabled the country to excel in global innovation rankings. The episode concludes with a candid discussion of the disruptive forces that could shape the future of Swiss biotech, including geopolitical shifts, trends in reshoring, and the sector’s preparedness for unforeseen events. Tune in to understand why Switzerland remains a global leader in biotech and what it must do to maintain its competitive edge in an increasingly complex world.

● Feedback

● Subscribe (Get notified when new episodes are available. NO marketing!)

● Disclaimer  

● LinkedIn

In this episode of BioBiz Buzz, your host Mike Ward sits down with Sten R. Sörensen, CEO of Cereno Scientific, to explore how the Swedish biotech is pioneering a new era in rare cardiovascular and pulmonary disease therapeutics. 

Cereno’s lead candidates, CS1 and CS014, leverage epigenetic modulation through histone deacetylase inhibition (HDACi) to address the root causes of diseases like pulmonary arterial hypertension (PAH) and idiopathic pulmonary fibrosis (IPF), aiming to reverse pathological remodeling and prevent thrombosis-without the bleeding risks of traditional therapies. 

Sörensen discusses the company’s strategic pivot to rare diseases, the science behind their innovative pipeline, and the impact of recent SEK250 million financing on accelerating clinical programs. The conversation also highlights Cereno’s approach to partnerships, regulatory milestones, and the transformative potential of targeting gene expression in cardiovascular drug development. 

Tune in for a deep dive into the future of disease-modifying therapies and the milestones shaping Cereno’s journey in 2025 

● Feedback

● Subscribe (Get notified when new episodes are available. NO marketing!)

● Disclaimer  

● LinkedIn

This episode of BioBiz Buzz spotlights the rapidly growing global markets for erectile dysfunction (ED) and premature ejaculation (PE), conditions impacting over 500 million men worldwide. 

Your host Mike Ward interviews Elin Trampe, CEO of Dicot Pharma, who discusses the company’s innovative drug candidate, LIB-01. 

Unlike conventional therapies, LIB-01 introduces a novel mechanism of action and offers a significantly longer efficacy window, 28 days after a brief 3-day dosing according to exploratory data in the phase 1 trial, potentially transforming the standard of care for both ED and PE. 

Trampe shares insights on the drug’s clinical progress, the company’s strategic partnerships, and efforts to reduce the stigma surrounding sexual health. 

● Feedback

● Subscribe (Get notified when new episodes are available. NO marketing!)

● Disclaimer  

● LinkedIn

This episode of BioBiz Buzz features Dr. Monika Paule, CEO and co-founder of Caszyme, a pioneering Lithuanian biotech company at the forefront of CRISPR-Cas technology. 

Your host Mike Ward explores how Caszyme is expanding the boundaries of gene editing through novel enzyme discovery, delivery optimization, and strategic collaborations, enabling breakthroughs in therapeutics, diagnostics, and sustainable agriculture. 

Dr. Paule discusses Caszyme’s unique approach to engineering smaller, more versatile Cas enzymes, their impact on treating genetic diseases, and the challenges of translating cutting-edge science into clinical and commercial success. 

The conversation also addresses the importance of diversity in biotech leadership and Caszyme’s vision for a more inclusive and sustainable future, highlighting the transformative potential and ongoing challenges of the CRISPR revolution.

● Feedback

● Subscribe (Get notified when new episodes are available. NO marketing!)

● Disclaimer  

● LinkedIn